Suppr超能文献

儿童慢性风湿性疾病患者使用抗 TNF-α 药物治疗结核是否安全?

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

机构信息

Infectious Diseases, Clinical Immunology and Allergy Division, Department of Pediatrics, Cerrahpasa Medical School, Istanbul University, Cerrahpasa, Istanbul, Turkey.

出版信息

Rheumatol Int. 2012 Sep;32(9):2675-9. doi: 10.1007/s00296-011-2030-8. Epub 2011 Jul 26.

Abstract

To determine the incidence of latent tuberculosis infection and evaluate the follow-up protocol of the patients diagnosed with juvenile idiopathic arthritis (JIA) and other chronic rheumatologic diseases treated with anti-TNF-α treatment (etanercept, infliximab, adalimumab) in Turkey, 144 patients were evaluated retrospectively for the development of tuberculosis. Patients were evaluated every 6 months for tuberculosis using history, physical examination, tuberculin skin test (TST), chest radiographs, and, when required, examination of sputum/early morning gastric aspirates for acid-fast bacilli and chest tomography. A tuberculin skin test over 10 mm induration was interpreted as positive. Patients were diagnosed with JIA (n = 132), enthesitis-related arthritis (ERA; n = 14), juvenile psoriatic arthritis (JPsA; n = 4), chronic idiopathic uveitis (n = 4), and chronic arthritis related to FMF (n = 8). Mean age was 12.25 ± 3.96 years (4.08-19.41 years), mean duration of illness was 5.86 ± 3.77 years (0.66-15 years), and the mean duration of anti-TNF-α treatment was 2.41 ± 1.47 years (0.6-7 years). Anti-TNF-α agents prescribed were etanercept (n = 133), infliximab (n = 30), and adalimumab (n = 6). When unresponsive to one anti-TNF-α therapy, patients were switched to another. There was no history of contact with individuals having tuberculosis. During follow-up, seven patients (4.8%) with positive TST were given INH prophylaxis. One oligoarticular JIA patient (0.69%) diagnosed with secondary uveitis who had been followed for 5 years and had been using infliximab for 2 years, developed a positive Quantiferon-TB test while on INH prophylaxis. He was started on an anti-tuberculosis drug regimen. In conclusion, anti-TNF-α treatment in children with chronic inflammatory disease is safe. Follow-up every 6 months of children on anti-TNF-α treatment with respect to tuberculosis by the pediatric infectious disease department is important to prevent possible complications.

摘要

为了确定潜伏性结核感染的发生率,并评估在土耳其接受抗 TNF-α 治疗(依那西普、英夫利昔单抗、阿达木单抗)的青少年特发性关节炎(JIA)和其他慢性风湿性疾病患者的随访方案,对 144 例患者进行了回顾性结核病评估。患者每 6 个月接受一次结核病评估,包括病史、体格检查、结核菌素皮肤试验(TST)、胸部 X 光片,以及必要时检查痰/清晨胃液中的抗酸杆菌和胸部 CT。硬结直径超过 10 毫米的结核菌素皮肤试验被解释为阳性。患者被诊断为 JIA(n=132)、附着点相关关节炎(ERA;n=14)、青少年银屑病关节炎(JPsA;n=4)、慢性特发性葡萄膜炎(n=4)和 FMF 相关慢性关节炎(n=8)。平均年龄为 12.25±3.96 岁(4.08-19.41 岁),平均病程为 5.86±3.77 年(0.66-15 年),抗 TNF-α 治疗的平均持续时间为 2.41±1.47 年(0.6-7 年)。处方的抗 TNF-α 药物为依那西普(n=133)、英夫利昔单抗(n=30)和阿达木单抗(n=6)。当一种抗 TNF-α 治疗无效时,患者会被切换到另一种药物。患者均无结核病接触史。在随访期间,7 例 TST 阳性患者(4.8%)接受了 INH 预防治疗。1 例寡关节炎 JIA 患者(0.69%),继发葡萄膜炎,随访 5 年,使用英夫利昔单抗 2 年,在接受 INH 预防治疗时,定量干扰素-TB 检测呈阳性。他开始接受抗结核药物治疗。总之,儿童慢性炎症性疾病使用抗 TNF-α 治疗是安全的。儿科传染病科每 6 个月对接受抗 TNF-α 治疗的儿童进行结核病随访,对于预防可能的并发症非常重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验